Safety and Varicella Outcomes in In Utero–Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program
Open Access
- 27 November 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 9 (4) , 449-453
Abstract
Background: Infants exposed to varicella zoster virus (VZV) in utero ≤5 days before or ≤48 hours after delivery and preterm infants are at high risk for varicella complications. An expanded-access program assessed varicella outcomes after administration of varicella zoster immune globulin (human) (VARIZIG) in a real-world setting.Methods: In this open-label, expanded-access program, high-risk infants received ≤125 IU/10 kg of VARIZIG (NCT00338442). VZV outcomes and safety were assessed.Results: There were 43 newborns exposed to VZV in utero and 80 preterm infants exposed to VZV; >80% received VARIZIG within 96 hours of reported exposure. When varicella outcomes were available, varicella occurred in 7 of 38 (18%) in utero–exposed newborns and zero of 65 preterm infants. Varicella-related complications were reported in 3 in utero–exposed newborns (3 with >100 lesions, 1 each with encephalitis and pneumonia). Adverse events were reported for 16% of in utero–exposed newborns and 25% of preterm infants, but few were considered related to VARIZIG. There were no deaths attributable to varicella or VARIZIG.Conclusions: Varicella incidence and morbidity were low in in utero–exposed infants and zero in preterm infants who received prophylactic VARIZIG. There were few VARIZIG-related safety concerns.Keywords
Funding Information
- Cangene Corporation
This publication has 24 references indexed in Scilit:
- Mannose 6-Phosphate Receptor Dependence of Varicella Zoster Virus Infection In Vitro and in the Epidermis during Varicella and ZosterCell, 2004
- Placental transport of immunoglobulin GVaccine, 2003
- Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella.Archives of Disease in Childhood, 1993
- OUTCOME IN NEWBORN BABIES GIVEN ANTI-VARICELLA-ZOSTER IMMUNOGLOBULIN AFTER PERINATAL MATERNAL INFECTION WITH VARICELLA-ZOSTER VIRUSThe Lancet, 1989
- Varicella-Zoster Immune Globulin for the Prevention of ChickenpoxAnnals of Internal Medicine, 1984
- Evaluation of Varicella-Zoster Immune Globulin: Protection of Immunosuppressed Children after Household Exposure to VaricellaThe Journal of Infectious Diseases, 1983
- Congenital Varicella in Term Infants: Risk ReconsideredThe Journal of Infectious Diseases, 1974
- Zoster Immune GlobulinNew England Journal of Medicine, 1974
- Prevention of Varicella by Zoster Immune GlobulinNew England Journal of Medicine, 1969
- Modification of Chicken Pox in Family Contacts by Administration of Gamma GlobulinNew England Journal of Medicine, 1962